Literature DB >> 14747961

MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases.

Daniel Vanel1, Sylvie Bonvalot, Jean Marc Guinebretière, Peter Petrow, Clarisse Dromain, Hubert Caillet.   

Abstract

PURPOSE: To prospectively evaluate the use of MRI with dynamic sequences during isolated limb perfusion (ILP) for soft tissue sarcomas, an aggressive local treatment using very high-dose chemotherapy and tumor necrosis factor aimed at avoiding limb amputation. DESIGN AND PATIENTS: Twenty-six patients were referred for ILP over one and a half years; eight were excluded as the lesions were either too proximal or suspicious inflammatory changes without tumor were found on the initial MRI, or the vascular status was poor. The indications for ILP were: vessel nerve involvement (13), multiple lesions (8), tumor size (4) or the presence of pulmonary metastases (2). MRI was performed 1 and 2 months after ILP, immediately prior to surgery and histological analysis. The MR examinations included T1-weighted SE and fast SE T2-weighted fat-saturated sequences, as well as dynamic sequences (T1-weighted SE repeated six times every 40 s), displaying the maximum intensity slope in each pixel.
RESULTS: The tumor had disappeared in three patients. One patient still had histologically proven isolated widespread tumor cells without a mass. The tumor size had increased in two patients. In six patients, the size of the tumor had not changed but it had become completely necrotic, with a thin wall. In three patients, after an initially good result MRI demonstrated that the tumor wall had become thickened from 1 to 2 months after ILP. Dynamic MRI was mainly useful during the initial examination, demonstrating two patients with inflammatory changes without tumor. Three amputations and a second ILP were proposed based on poor results. Conservative limb-sparing surgery was successful in the other cases.
CONCLUSION: MRI proved valuable in demonstrating the variable responses to ILP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747961     DOI: 10.1007/s00256-003-0726-x

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  14 in total

1.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

Authors:  A M Eggermont; H Schraffordt Koops; D Liénard; B B Kroon; A N van Geel; H J Hoekstra; F J Lejeune
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

2.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

3.  Statistical analysis of MRI parameters predicting malignancy in 141 soft tissue masses.

Authors:  A M De Schepper; F A Ramon; H R Degryse
Journal:  Rofo       Date:  1992-06

4.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.

Authors:  J Bickels; E R Manusama; M Gutman; A M Eggermont; Y Kollender; S Abu-Abid; A N Van Geel; D Lev-Shlush; J M Klausner; I Meller
Journal:  Eur J Surg Oncol       Date:  1999-10       Impact factor: 4.424

Review 5.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

6.  Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion.

Authors:  K L Verstraete; Y De Deene; H Roels; A Dierick; D Uyttendaele; M Kunnen
Journal:  Radiology       Date:  1994-09       Impact factor: 11.105

7.  MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations.

Authors:  D Vanel; L G Shapeero; T De Baere; R Gilles; A Tardivon; J Genin; J M Guinebretière
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

8.  FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.

Authors:  R J van Ginkel; H J Hoekstra; J Pruim; O E Nieweg; W M Molenaar; A M Paans; A T Willemsen; W Vaalburg; H S Koops
Journal:  J Nucl Med       Date:  1996-06       Impact factor: 10.057

9.  Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging.

Authors:  H J van der Woude; J L Bloem; H C Holscher; M A Nooy; A H Taminiau; J Hermans; T H Falke; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

10.  Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging.

Authors:  T de Baere; D Vanel; L G Shapeero; A Charpentier; P Terrier; M di Paola
Journal:  Radiology       Date:  1992-11       Impact factor: 11.105

View more
  3 in total

1.  TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature.

Authors:  L E Podleska; K Funk; L Umutlu; F Grabellus; G Taeger; H de Groot
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

Review 2.  Musculoskeletal primary tumours: treatment evaluation and detection of recurrences.

Authors:  Daniel Vanel
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

3.  The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.

Authors:  Benjamin Schwindenhammer; Lars Erik Podleska; Andrea Kutritz; Sebastian Bauer; Sien-Yi Sheu; Georg Taeger; Kurt Werner Schmid; Florian Grabellus
Journal:  World J Surg Oncol       Date:  2013-08-12       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.